BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22244256)

  • 21. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.
    Leruez-Ville M; Seng R; Morand P; Boufassa F; Boue F; Deveau C; Rouzioux C; Goujard C; Seigneurin JM; Meyer L
    HIV Med; 2012 Sep; 13(8):479-87. PubMed ID: 22414000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
    Van Baarle D; Wolthers KC; Hovenkamp E; Niesters HG; Osterhaus AD; Miedema F; Van Oers MH
    J Infect Dis; 2002 Aug; 186(3):405-9. PubMed ID: 12134237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
    AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
    Sharma A; Bajpai J; Raina V; Mohanti BK
    Indian J Cancer; 2010; 47(1):35-9. PubMed ID: 20071788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
    de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
    HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
    Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U
    Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study.
    Castillo JJ; Beltran BE; Bibas M; Bower M; Collins JA; Cwynarski K; Diez-Martin JL; Hernandez-Ilizaliturri F; Horwitz SM; Montoto S; Pantanowitz L; Ribera JM; Vose JM
    Am J Hematol; 2011 Mar; 86(3):256-61. PubMed ID: 21328430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
    Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
    AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection.
    van Baarle D; Kostense S; Hovenkamp E; Ogg G; Nanlohy N; Callan MF; Dukers NH; McMichael AJ; van Oers MH; Miedema F
    AIDS; 2002 Oct; 16(15):2001-11. PubMed ID: 12370498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr viral load as a marker of lymphoma in AIDS patients.
    Fan H; Kim SC; Chima CO; Israel BF; Lawless KM; Eagan PA; Elmore S; Moore DT; Schichman SA; Swinnen LJ; Gulley ML
    J Med Virol; 2005 Jan; 75(1):59-69. PubMed ID: 15543571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
    Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
    Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
    Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
    J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
    Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
    O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
    J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.